{
    "nct_id": "NCT03258398",
    "official_title": "A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer",
    "inclusion_criteria": "* ECOG performance status of 0, 1, or 2\n* Pathologically documented diagnosis of colorectal adenocarcinoma.\n* Progressed on or intolerant of at least 2 prior cancer therapy regimens administered for metastatic disease.\n* Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥3 weeks before the start of study therapy.\n* Part 2 only: Presence of radiographically measurable disease (defined as the presence of ≥1 lesion that measures ≥10 mm [≥15 mm for lymph nodes]). Measurable disease that was previously radiated is only permitted if progressing.\n* Agrees to undergo a pretreatment and a post-treatment biopsy.\n* Microsatellite stable disease determined by IHC and/or polymerase chain reaction (PCR).\n* Adequate bone marrow function\n* Adequate hepatic function\n* Adequate renal function\n* Normal coagulation profile\n* Negative antiviral serology\n* Female subjects of childbearing potential must not be pregnant or breastfeeding\n* Willingness to use protocol-recommended methods of contraception or to abstain from heterosexual intercourse from start of therapy until at lest 30 days after the last dose of study therapy\n* Life expectancy of ≥3 months.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of another malignancy except for adequately treated local basal cell or squamous cell carcinoma of the skin; in situ cervical or breast carcinoma; adequately treated, papillary, noninvasive bladder cancer; other adequately treated Stage 1 or 2 cancers currently in complete remission, or any other cancer that has been in complete remission for ≥2 years.\n* Known symptomatic brain metastases requiring ≥10 mg/day of prednisolone (or its equivalent).\n* Significant cardiovascular disease.\n* Significant screening ECG abnormalities.\n* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent.\n* Known history of colitis, inflammatory bowel disease, pneumonitis, or pulmonary fibrosis.\n* Ongoing risk for bleeding due to active peptic ulcer disease or bleeding diathesis.\n* Evidence of an ongoing systemic bacterial, fungal, or viral infection.\n* Any condition that may impact the subject's ability to swallow oral medications.\n* Major surgery within 4 weeks before the start of study therapy.\n* Prior solid organ or bone marrow progenitor cell transplantation.\n* Prior therapy with any known inhibitor of MNK-1 or MNK-2.\n* Prior therapy with any of the following: PD-1, PD-L1, CTLA4 antibody, or any other drug targeting T cell checkpoint pathways.\n* Prior high dose chemotherapy requiring stem cell rescue.\n* Intolerance to or prior severe (≥Grade 3) allergic or anaphylactic reaction to infused antibodies or infused therapeutic proteins.\n* Vaccination within 4 weeks of the first dose of avelumab and while on study.\n* Ongoing immunosuppressive therapy.\n* Use of a strong inhibitor or inducer of cytochrome P450 3A4 (CYP3A4) within 7 days prior to the start of study therapy or expected requirement for use of a strong CYP3A4 inhibitor or inducer during study therapy.\n* Previously received investigational product in a clinical trial within 30 days or within 5 elimination half lives (whichever is longer) prior to the start of study therapy, or is planning to take part in another clinical trial while participating in this study.\n* Has any illness, medical condition, organ system dysfunction, or social situation, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent, adversely affect the subject's ability to cooperate and participate in the study, or compromise the interpretation of study results",
    "miscellaneous_criteria": ""
}